By Mrinalika Roy and Kamal Choudhury
(Reuters) – In a significant boost for its financial outlook, McKesson (MCK) announced on Tuesday an increase in its profit forecast, demonstrating its strategic shift towards high-margin sectors, particularly cancer therapeutics, to drive future growth.
The Texas-based pharmaceutical distributor has raised its expectations for adjusted earnings for fiscal 2026 to a range of $38.05 to $38.55 per share, revising upwards from the previous estimate of $37.10 to $37.90.
Additionally, McKesson has updated its long-term adjusted earnings growth target, now aiming for an annual growth rate of 13% to 16%, as opposed to the prior range of 12% to 14%.
The company’s stock reacted positively to the news, rising approximately 6% in after-hours trading.
CEO Brian Tyler highlighted the company’s strong operational performance and disciplined execution as critical factors that will create a “meaningful impact across the healthcare ecosystem.”
Last week, McKesson unveiled a reorganization plan that includes the establishment of a newly-defined oncology and multispecialty unit.
This segment, which encompasses cancer care, retina services, and specialized drug distribution, is projected to grow at an impressive annual rate of 13% to 16%, making it the fastest-growing division within the company.
In contrast, its prescription technology solutions division—aids to biopharma companies with patient access and compliance—is anticipated to achieve a growth of 10% to 13% per year.
The traditional North American pharmaceutical segment is expected to see more modest growth, ranging from 5% to 8%.
Market analysts view these updates as promising signs for McKesson’s growth trajectory, especially ahead of its investor day scheduled for later on Tuesday.
Leerink Partners analysts remarked that this announcement serves as a positive indicator for McKesson’s future growth compounding capabilities.
McKesson has also been actively enhancing its presence in the oncology market through strategic acquisitions, including the substantial $2.49 billion investment to acquire a controlling interest in Core Ventures, a business services firm associated with Florida Cancer Specialists.
Evercore ISI analyst Elizabeth Anderson commented that Tuesday’s announcement exceeded expectations and suggested the current operating environment would be a focal point during the upcoming investor day, especially given recent concerns regarding drug pricing.
McKesson further indicated plans to update investors about the anticipated separation of its medical-surgical solutions unit.
(Reporting by Mrinalika Roy and Kamal Choudhury in Bengaluru; Editing by Shreya Biswas)
This rewritten content retains the format and key points from the original article while ensuring uniqueness and suitability for a WordPress platform.
